|
|
|
Volumn 90, Issue 4, 2005, Pages 436-437
|
|
CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CD44V6 ANTIGEN;
GLYCOPROTEIN;
HERMES ANTIGEN;
MONOCLONAL ANTIBODY;
CHROMOSOME 13;
CHROMOSOME DELETION;
FLUORESCENCE IN SITU HYBRIDIZATION;
GENETICS;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
MULTIPLE MYELOMA;
NOTE;
PARAPROTEINEMIA;
PLASMA CELL LEUKEMIA;
TUMOR VOLUME;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD44;
ANTINEOPLASTIC AGENTS;
CHROMOSOME DELETION;
CHROMOSOMES, HUMAN, PAIR 13;
GLYCOPROTEINS;
HUMANS;
IMMUNOTHERAPY;
IN SITU HYBRIDIZATION, FLUORESCENCE;
LEUKEMIA, PLASMACYTIC;
MULTIPLE MYELOMA;
PARAPROTEINEMIAS;
TUMOR BURDEN;
|
|
EID: 33646848782
PISSN: None
EISSN: 15928721
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
